Illumina, Inc. (NASDAQ:ILMN ) Annual Evercore ISI HealthCONx Healthcare Conference December 3, 2024 9:00 AM ET Company Participants Ankur Dhingra - CFO Sallilyn Schwartz - VP of Investor Relations Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Great. Thanks, everyone, for joining us this afternoon.
Illumina, Inc. (NASDAQ:ILMN ) Wolfe Research 2024 Healthcare Conference Call November 20, 2024 9:20 AM ET Company Participants Ankur Dhingra - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research Doug Schenkel All right. Good morning, everybody.
Illumina's new TSO 500 v2 assay aims to enable CGP of tumors, bolstering its TruSight Oncology portfolio.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Explore how Illumina's (ILMN) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Illumina is the leader in the undisputed Next Generation Sequencing market. Grail divestment is behind, enabling a margin expansion and fueling a more robust cash flow generation. The stock was down after hours, as much good news has been priced in the recent rally.
Illumina's third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business.
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Illumina, Inc. (NASDAQ:ILMN ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Corporate Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research Puneet Souda - Leerink Partners Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Tycho Peterson - Jefferies David Westenberg - Piper Sandler Conor McNamara - RBC Capital Markets Dan Arias - Stifel Patrick Donnelly - Citi Subha Nambi - Guggenheim Sung Ji Nam - Scotiabank Ben Mee - Stephens Dan Leonard - UBS Operator Good day, ladies and gentlemen, and welcome to the Third Quarter 2024 Illumina Earnings Conference Call. At this time, all participants are in a listen-only mode.
Illumina (ILMN) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $0.33 per share a year ago.
Illumina (ILMN) is trading down guiding a 3% decline in revenue. George Tsilis believes the company is still notable despite the market's reaction.
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Illumina (ILMN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.